You have to be signed in to use this resource.
Analytical considerations for detecting and quantifying novel synthetic opioids, including ‘nitazenes', in biological samples
In recent years, novel synthetic opioids (NSOs) have been detected in drug seizures and in biological samples in the United Kingdom. These compounds are highly potent, and so keeping current with which compounds are in circulation in the illicit drug market in the UK, and how best to detect them in a range of samples is important to inform public health decisions, and to minimise the risk of false negative analyses. This webinar will discuss the analytical considerations for maximising detection of a range of these compounds, including how to attempt to keep ahead of newly-emerging analogues.
Resource details
| Contributed by: | Pathology Portal |
| Authored by: |
|
| Licence: | © All rights reserved More information on licences |
| First contributed: | 12 February 2026 |
| Audience access level: | General user |
Share this resource
Report an issue with this resource
You may report a resource, for example, if there is an issue with copyright infringement, breach of personal data, factual inaccuracies, typing errors or safety concerns. The type of issue will determine whether the resource is immediately removed from the platform or if the contributor is asked to make amendments. You can report a resource from the resource information page or by contacting the Learning Hub support team.
You can contact the Learning Hub support team by completing the support form or if you have a general enquiry you can email enquiries@learninghub.nhs.uk.